{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:30:59Z","timestamp":1787315459026,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T00:00:00Z","timestamp":1573430400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T00:00:00Z","timestamp":1573430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s10620-019-05934-7","type":"journal-article","created":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T06:02:56Z","timestamp":1573452176000},"page":"22-30","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Managing Patients with Inflammatory Bowel Disease Who Develop Prostate Cancer"],"prefix":"10.1007","volume":"65","author":[{"given":"Jaehyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7758-3257","authenticated-orcid":false,"given":"Linda A.","family":"Feagins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,11]]},"reference":[{"key":"5934_CR1","unstructured":"Key Statistics for Prostate Cancer | Prostate Cancer Facts. www.cancer.org\/cancer\/prostate-cancer\/about\/key-statistics.html. Accessed 15 Feb 2019"},{"key":"5934_CR2","unstructured":"Survival Rates for Prostate Cancer. American Cancer Society. www.cancer.org\/cancer\/prostate-cancer\/detection-diagnosis-staging\/survival-rates.html. Accessed 15 Feb 2019"},{"key":"5934_CR3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/ajg.2010.300","volume":"106","author":"B Shen","year":"2011","unstructured":"Shen B, Angermeier KW, Remzi FH, Katz S. Screening and diagnosis of prostate cancer in patients with ileal pouch-anal anastomosis: consensus from an expert panel. Am J Gastroenterol. 2011;106:186\u2013189.","journal-title":"Am J Gastroenterol"},{"key":"5934_CR4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.urology.2007.09.029","volume":"71","author":"R Hara","year":"2008","unstructured":"Hara R, Jo Y, Fujii T, et al. Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy. Urology. 2008;71:191\u2013195.","journal-title":"Urology"},{"key":"5934_CR5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1445-2197.2005.03284.x","volume":"75","author":"J Miller","year":"2005","unstructured":"Miller J, Perumalla C, Heap G. Complications of transrectal versus transperineal prostate biopsy. ANZ J Surg. 2005;75:48\u201350.","journal-title":"ANZ J Surg"},{"key":"5934_CR6","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1111\/j.1464-410X.2011.10621.x","volume":"108","author":"B Challacombe","year":"2011","unstructured":"Challacombe B, Dasgupta P, Patel U, Amoroso P, Kirby R. Recognizing and managing the complications of prostate biopsy. BJU Int. 2011;108:1233\u20131234.","journal-title":"BJU Int"},{"key":"5934_CR7","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.urology.2013.02.019","volume":"81","author":"P Pepe","year":"2013","unstructured":"Pepe P, Aragona F. Morbidity after transperineal prostate biopsy in 3000 patients undergoing 12 versus 18 versus more than 24 needle cores. Urology. 2013;81:1142\u20131146.","journal-title":"Urology"},{"key":"5934_CR8","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/gut.48.4.526","volume":"48","author":"JA Eaden","year":"2001","unstructured":"Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526\u2013535.","journal-title":"Gut"},{"key":"5934_CR9","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1053\/j.gastro.2005.12.037","volume":"130","author":"T Jess","year":"2006","unstructured":"Jess T, Loftus EV Jr, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted county, Minnesota. Gastroenterology. 2006;130:1039\u20131046.","journal-title":"Gastroenterology"},{"key":"5934_CR10","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1053\/j.gastro.2007.08.001","volume":"133","author":"RB Gupta","year":"2007","unstructured":"Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133:1099\u20131105. quiz 340-1.","journal-title":"Gastroenterology"},{"key":"5934_CR11","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/ajg.2009.760","volume":"105","author":"N Pedersen","year":"2010","unstructured":"Pedersen N, Duricova D, Elkjaer M, Gamborg M, Munkholm P, Jess T. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies. Am J Gastroenterol. 2010;105:1480\u20131487.","journal-title":"Am J Gastroenterol"},{"key":"5934_CR12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/ibd\/izx046","volume":"24","author":"CA Mosher","year":"2018","unstructured":"Mosher CA, Brown GR, Weideman RA, et al. Incidence of colorectal cancer and extracolonic cancers in veteran patients with inflammatory bowel disease. Inflamm Bowel Dis. 2018;24:617\u2013623.","journal-title":"Inflamm Bowel Dis"},{"key":"5934_CR13","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.eururo.2018.11.039","volume":"75","author":"JA Burns","year":"2019","unstructured":"Burns JA, Weiner AB, Catalona WJ, et al. Inflammatory bowel disease and the risk of prostate cancer. Eur Urol. 2019;75:846\u2013852.","journal-title":"Eur Urol"},{"key":"5934_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2019.07.003","author":"M Chen","year":"2019","unstructured":"Chen M, Yuan C, Xu T. An increase in prostate cancer diagnosis during inflammatory bowel disease: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2019. https:\/\/doi.org\/10.1016\/j.clinre.2019.07.003.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"5934_CR15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrurol.2017.167","volume":"15","author":"KS Sfanos","year":"2018","unstructured":"Sfanos KS, Yegnasubramanian S, Nelson WG, De Marzo AM. The inflammatory microenvironment and microbiome in prostate cancer development. Nat Rev Urol. 2018;15:11\u201324.","journal-title":"Nat Rev Urol"},{"key":"5934_CR16","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/j.1464-410X.2012.10929.x","volume":"110","author":"SD Chung","year":"2012","unstructured":"Chung SD, Keller JJ, Lin HC. A case-control study of chronic prostatitis\/chronic pelvic pain syndrome and colorectal cancer. BJU Int. 2012;110:550\u2013554.","journal-title":"BJU Int"},{"key":"5934_CR17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41585-019-0157-7","volume":"16","author":"KS Sfanos","year":"2019","unstructured":"Sfanos KS, Joshu CE. IBD as a risk factor for prostate cancer: what is the link? Nat Rev Urol. 2019;16:271\u2013272.","journal-title":"Nat Rev Urol"},{"key":"5934_CR18","first-page":"802","volume":"42","author":"YH Ling","year":"1992","unstructured":"Ling YH, Chan JY, Beattie KL, Nelson JA. Consequences of 6-thioguanine incorporation into DNA on polymerase, ligase, and endonuclease reactions. Mol Pharmacol. 1992;42:802\u2013807.","journal-title":"Mol Pharmacol"},{"key":"5934_CR19","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1074\/jbc.M204243200","volume":"278","author":"L Somerville","year":"2003","unstructured":"Somerville L, Krynetski EY, Krynetskaia NF, et al. Structure and dynamics of thioguanine-modified duplex DNA. J Biol Chem. 2003;278:1005\u20131011.","journal-title":"J Biol Chem"},{"key":"5934_CR20","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1136\/gutjnl-2013-305763","volume":"63","author":"L Beaugerie","year":"2014","unstructured":"Beaugerie L, Carrat F, Colombel JF, et al. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut. 2014;63:1416\u20131423.","journal-title":"Gut"},{"key":"5934_CR21","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1432-2277.2006.00330.x","volume":"19","author":"HM Kauffman","year":"2006","unstructured":"Kauffman HM, Cherikh WS, McBride MA, Cheng Y, Hanto DW. Post-transplant de novo malignancies in renal transplant recipients: the past and present. Transpl Int. 2006;19:607\u2013620.","journal-title":"Transpl Int"},{"key":"5934_CR22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2036.2010.04330.x","volume":"32","author":"MA Smith","year":"2010","unstructured":"Smith MA, Irving PM, Marinaki AM, Sanderson JD. Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther. 2010;32:119\u2013130.","journal-title":"Aliment Pharmacol Ther"},{"key":"5934_CR23","doi-asserted-by":"publisher","DOI":"10.1177\/1756284818817293","author":"S Sebastian","year":"2019","unstructured":"Sebastian S, Neilaj S. Practical guidance for the management of inflammatory bowel disease in patients with cancer. Which treatment? Therap Adv Gastroenterol. 2019;. https:\/\/doi.org\/10.1177\/1756284818817293.","journal-title":"Therap Adv Gastroenterol"},{"key":"5934_CR24","first-page":"168","volume":"65","author":"H Tian","year":"2007","unstructured":"Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65:168\u2013173.","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"5934_CR25","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/ard.2008.093690","volume":"68","author":"C Salliot","year":"2009","unstructured":"Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009;68:1100\u20131104.","journal-title":"Ann Rheum Dis"},{"key":"5934_CR26","doi-asserted-by":"crossref","first-page":"33894","DOI":"10.1038\/srep33894","volume":"6","author":"S Zhu","year":"2016","unstructured":"Zhu S, Wang Q, Jiang J, Luo Y, Sun Z. A conjugate of methotrexate and an analog of luteinizing hormone releasing hormone shows increased efficacy against prostate cancer. Sci Rep. 2016;6:33894.","journal-title":"Sci Rep"},{"key":"5934_CR27","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.2014.5613","volume":"311","author":"N Nyboe Andersen","year":"2014","unstructured":"Nyboe Andersen N, Pasternak B, Basit S, et al. Association between tumor necrosis factor-alpha antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA. 2014;311:2406\u20132413.","journal-title":"JAMA"},{"key":"5934_CR28","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1002\/art.30247","volume":"63","author":"P Raaschou","year":"2011","unstructured":"Raaschou P, Simard JF, Neovius M, Askling J. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis Rheum. 2011;63:1812\u20131822.","journal-title":"Arthritis Rheum"},{"key":"5934_CR29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/rr.2000.5269","volume":"7","author":"I Penn","year":"2000","unstructured":"Penn I. Cancers in renal transplant recipients. Adv Ren Replace Ther. 2000;7:147\u2013156.","journal-title":"Adv Ren Replace Ther"},{"key":"5934_CR30","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/00007890-199304000-00011","volume":"55","author":"I Penn","year":"1993","unstructured":"Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation. 1993;55:742\u2013747.","journal-title":"Transplantation"},{"key":"5934_CR31","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cgh.2015.07.037","volume":"14","author":"J Axelrad","year":"2016","unstructured":"Axelrad J, Bernheim O, Colombel JF, et al. Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14:58\u201364.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5934_CR32","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ecco-jcc\/jjv141","volume":"9","author":"V Annese","year":"2015","unstructured":"Annese V, Beaugerie L, Egan L, et al. European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis. 2015;9:945\u2013965.","journal-title":"J Crohns Colitis"},{"key":"5934_CR33","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.4049\/jimmunol.168.11.5699","volume":"168","author":"C Parham","year":"2002","unstructured":"Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168:5699\u20135708.","journal-title":"J Immunol"},{"key":"5934_CR34","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","volume":"168","author":"KA Papp","year":"2013","unstructured":"Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5\u00a0years of follow-up. Br J Dermatol. 2013;168:844\u2013854.","journal-title":"Br J Dermatol"},{"key":"5934_CR35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40265-013-0176-2","volume":"74","author":"MH Mosli","year":"2014","unstructured":"Mosli MH, Rivera-Nieves J, Feagan BG. T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects. Drugs. 2014;74:297\u2013311.","journal-title":"Drugs"},{"key":"5934_CR36","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","volume":"66","author":"JF Colombel","year":"2017","unstructured":"Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease. Gut. 2017;66:839\u2013851.","journal-title":"Gut"},{"key":"5934_CR37","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1136\/gutjnl-2013-305300","volume":"62","author":"O Bernheim","year":"2013","unstructured":"Bernheim O, Colombel JF, Ullman TA, Laharie D, Beaugerie L, Itzkowitz SH. The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut. 2013;62:1523\u20131528.","journal-title":"Gut"},{"key":"5934_CR38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.gastro.2011.09.034","volume":"142","author":"E Louis","year":"2012","unstructured":"Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn\u2019s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142:63\u201370.e5. quiz e31.","journal-title":"Gastroenterology"},{"key":"5934_CR39","first-page":"552","volume":"58","author":"S Tamada","year":"2017","unstructured":"Tamada S, Ninomiya N, Kitamoto K, et al. Comparative effectiveness of radical prostatectomy and curative radiotherapy in localized prostate cancer: long-term follow-up. J Radiat Res. 2017;58:552\u2013558.","journal-title":"J Radiat Res"},{"key":"5934_CR40","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0360-3016(99)00374-0","volume":"46","author":"CG Willett","year":"2000","unstructured":"Willett CG, Ooi CJ, Zietman AL, et al. Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms. Int J Radiat Oncol Biol Phys. 2000;46:995\u2013998.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5934_CR41","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.1200\/JCO.2006.07.9954","volume":"24","author":"AB Chen","year":"2006","unstructured":"Chen AB, D\u2019Amico AV, Neville BA, Earle CC. Patient and treatment factors associated with complications after prostate brachytherapy. J Clin Oncol. 2006;24:5298\u20135304.","journal-title":"J Clin Oncol"},{"key":"5934_CR42","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.clon.2018.06.007","volume":"30","author":"W Mohammed","year":"2018","unstructured":"Mohammed W, Hoskin P, Henry A, Gomez-Iturriaga A, Robinson A, Nikapota A. Short-term toxicity of high dose rate brachytherapy in prostate cancer patients with inflammatory bowel disease. Clin Oncol (R Coll Radiol). 2018;30:534\u2013538.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"5934_CR43","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.rpor.2016.10.005","volume":"22","author":"MM Gestaut","year":"2017","unstructured":"Gestaut MM, Swanson GP. Long term clinical toxicity of radiation therapy in prostate cancer patients with inflammatory bowel disease. Rep Pract Oncol Radiother. 2017;22:77\u201382.","journal-title":"Rep Pract Oncol Radiother"},{"key":"5934_CR44","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1016\/j.prro.2014.09.004","volume":"5","author":"CT Murphy","year":"2015","unstructured":"Murphy CT, Heller S, Ruth K, et al. Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease: patient selection and dosimetric parameters with modern treatment techniques. Pract Radiat Oncol. 2015;5:e215\u2013e222.","journal-title":"Pract Radiat Oncol"},{"key":"5934_CR45","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ijrobp.2006.05.027","volume":"66","author":"CA Peters","year":"2006","unstructured":"Peters CA, Cesaretti JA, Stone NN, Stock RG. Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease. Int J Radiat Oncol Biol Phys. 2006;66:424\u2013429.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5934_CR46","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz175","author":"LA Feagins","year":"2019","unstructured":"Feagins LA, Kim J, Chandrakumaran A, et al. Rates of adverse IBD-related outcomes for patients with IBD and concomitant prostate cancer treated with radiation therapy. Inflamm Bowel Dis. 2019. https:\/\/doi.org\/10.1093\/ibd\/izz175.","journal-title":"Inflamm Bowel Dis"},{"key":"5934_CR47","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.clon.2015.05.001","volume":"27","author":"D Tromp","year":"2015","unstructured":"Tromp D, Christie DR. Acute and late bowel toxicity in radiotherapy patients with inflammatory bowel disease: a systematic review. Clin Oncol (R Coll Radiol). 2015;27:536\u2013541.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"5934_CR48","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1016\/j.prro.2015.03.002","volume":"5","author":"S Cherian","year":"2015","unstructured":"Cherian S, Kittel JA, Reddy CA, et al. Safety and efficacy of iodine-125 permanent prostate brachytherapy in patients with J-pouch anastomosis after total colectomy for ulcerative colitis. Pract Radiat Oncol. 2015;5:e437\u2013e442.","journal-title":"Pract Radiat Oncol"},{"key":"5934_CR49","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/codi.14467","volume":"21","author":"AL Lightner","year":"2019","unstructured":"Lightner AL, Spinelli A, McKenna NP, Hallemeier CL, Fleshner P. Does external beam radiation therapy to the pelvis portend worse ileal pouch outcomes? An international multi-institution collaborative study. Colorectal Dis. 2019;21:219\u2013225.","journal-title":"Colorectal Dis"},{"key":"5934_CR50","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/COC.0000000000000010","volume":"38","author":"EC White","year":"2015","unstructured":"White EC, Murphy JD, Chang DT, Koong AC. Low toxicity in inflammatory bowel disease patients treated with abdominal and pelvic radiation therapy. Am J Clin Oncol. 2015;38:564\u2013569.","journal-title":"Am J Clin Oncol"},{"key":"5934_CR51","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.urology.2017.01.030","volume":"104","author":"PS Kirk","year":"2017","unstructured":"Kirk PS, Govani S, Borza T, et al. Implications of prostate cancer treatment in men with inflammatory bowel disease. Urology. 2017;104:131\u2013136.","journal-title":"Urology"},{"key":"5934_CR52","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.brachy.2012.04.008","volume":"12","author":"HH Pai","year":"2013","unstructured":"Pai HH, Keyes M, Morris WJ, Christie J. Toxicity after (125)I prostate brachytherapy in patients with inflammatory bowel disease. Brachytherapy. 2013;12:126\u2013133.","journal-title":"Brachytherapy"},{"key":"5934_CR53","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0360-3016(97)00583-X","volume":"40","author":"A Grann","year":"1998","unstructured":"Grann A, Wallner K. Prostate brachytherapy in patients with inflammatory bowel disease. Int J Radiat Oncol Biol Phys. 1998;40:135\u2013138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"5934_CR54","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00384-014-2103-8","volume":"30","author":"BW Chang","year":"2015","unstructured":"Chang BW, Kumar AM, Koyfman SA, Kalady M, Lavery I, Abdel-Wahab M. Radiation therapy in patients with inflammatory bowel disease and colorectal cancer: risks and benefits. Int J Colorectal Dis. 2015;30:403\u2013408.","journal-title":"Int J Colorectal Dis"},{"key":"5934_CR55","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0360-3016(01)01629-7","volume":"51","author":"DY Song","year":"2001","unstructured":"Song DY, Lawrie WT, Abrams RA, et al. Acute and late radiotherapy toxicity in patients with inflammatory bowel disease. Int J Radiat Oncol Biol Phys. 2001;51:455\u2013459.","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-05934-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-019-05934-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-019-05934-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T19:47:06Z","timestamp":1604951226000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-019-05934-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,11]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["5934"],"URL":"https:\/\/doi.org\/10.1007\/s10620-019-05934-7","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,11]]},"assertion":[{"value":"14 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"LAF had prior research funding from Takeda. JK has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}